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Specific therapy of digoxin intoxication in dogs by hybrid kidney to treat drug intoxication using this system. We have
overexpressing multidrug resistance protein. recently reported a unique hybrid type artificial kidney
Background. We have recently developed a unique hybrid
by culturing immortalized renal proximal tubule cellsartificial kidney, where the proximal tubular cell line, over-
(PCTL) with an introduction of multidrug resistance pro-expressing multidrug resistance protein, MDR-1 (PCTL-MDR),
was cultured on hollow fibers. While this module efficiently tein (MDR)-1 in the hollow fiber module [3]. That in
removed digoxin in vitro, its efficacy in vivo remained to be vitro study showed that this novel device selectively re-
determined.
moved the substrate of MDR-1, such as digoxin and doxo-Methods. The system was scaled up by connecting 10 simi-
rubicin, from perfusing culture medium. Furthermore,lar modules in parallel, with the MDR-1 (PCTL-MDR) over-
expressed proximal tubular cell line cultured as in our previous the capacity of drug removal by the system was estimated
study. The system was connected to dogs intoxicated with di- to be equivalent with that of normal human kidney if
goxin, a representative substrate of MDR-1. Blood was circu-
the device was scaled up 50 to 100 times. However, sincelated for 90 minutes through the system. Arterial and venous
that study did not determine the efficacy of our deviceblood concentrations of digoxin and inulin were monitored.
Complete blood cell count and granulocyte elastase were mea- in vivo, the purpose of our current study was to examine
sured before and at the end of the study. the efficacy of our system in vivo. We scaled up the
Results. By using the system with PCTL-MDR, the arterial
system by connecting 10 hollow fiber modules in paralleldigoxin concentration was dramatically decreased from 2.89
0.10 to 0.92  0.11 ng/mL, but not by the system with PCTL and applied this system to dogs with digoxin intoxication.
alone. The clearance was 22.4  2.1 and 1.5  0.2 mL/min for We evaluated not only the efficacy of the system, but
the PCTL-MDR and PCTL equipment, respectively. Inulin also its biocompatibility and related adverse reactions.was not transported in either system. White blood cell and
platelet counts were slightly reduced by the treatment while
hematocrit was unchanged; the granulocyte elastase concentra-
tion was slightly increased. METHODS
Conclusion. These data suggest that our new type of hybrid Animal preparationkidney can selectively remove digoxin sufficiently to reduce its
systemic blood concentration in dogs with digoxin intoxication. To establish an animal model of digoxin intoxication,
Taking previous studies into consideration, this system may be the drug was injected (625 g/kg, intramuscularly) in
a more powerful tool for the treatment of intoxication.
healthy dogs (body weight; 10 to 16 kg) every 12 hours
for three days before the experiment [4]. Twelve hours
after the final injection, the animals were anesthetizedAlthough hemoperfusion is frequently used for the
with an intravenous injection of pentobarbitrate-sodiumtreatment of drug intoxication [1], this maneuver has
(1 mg/kg). An additional injection was given when thesome disadvantages and its usage is limited [2]. Advances
animals awoke. Respiration was supported by a ventila-in molecular biology and cell culture systems enabled us
tor (350 mL tidal volume, 14 times/min; Respirator R-60;to develop a new type of hybrid organ. It may be possible
Ichikawa-Shinseido Co. Ltd., Tokyo, Japan). Electro-
cardiography and rectal temperature were monitoredKey words: artificial kidney, hollow-fiber membranes, MDR, biocom-
throughout the study. The cubital vein and femoral ar-patibility, organ replacement, renal proximal tubule cell line.
tery were cannulated and served as the blood access.
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Fig. 1. Schematic illustration of the hybrid
kidney for the dog. Ten hybrid modules were
connected in parallel for the treatment.
Preparation of the hybrid kidney modified Eagle’s medium (DMEM)/Ham’s F-12 with
10% fetal calf serum (FCS), 1 mL/min] in a CO2-incuba-The artificial hybrid kidney, designed especially for
tor that was maintained at 37C and 95% O2/5% CO2digoxin removal, has been described previously [3]. In
for eight days [3]. A part of the connected tubing wasbrief, PCTL, a renal proximal tubule cell line, was origi-
made of silicon to enhance gas exchange in the incubator.nally made by adding SV40 large T antigen to a primary
culture of rabbit S1 cells. cDNA of human MDR-1 was Evaluation of the hybrid kidney in digoxin-intoxicated dogs
introduced to the PCTL by electroporation [5]. Cells
For each experiment, ten modules were used that werethat were resistant to the highest concentration of col-
connected in parallel just before the treatment of digoxinchicine, a substrate of MDR-1, was cloned and named
intoxication (Fig. 1). Comparison of the efficacy betweenPCTL-MDR. This clone possesses 10 times greater
the systems treated with PCTL-MDR and PCTL wasamount of MDR-1 protein and about 100 times larger
evaluated by a randomized open cross-over design with
Km and Vmax values for digoxin than PCTL, while the a two-week interval. The treatment with PCTL served
transport capacity of paraaminohippurate (PAH) was as a control. On the day of the treatment, these modules
similar between the two cell lines. Transcellular inulin were transferred from the incubator to a temperature-
transport was negligible in both. controlled warm bath at 37C with 95%O2-oxygenizationTo make a hybrid kidney, hollow-fiber module for after the parallel connection. The culture medium inside
immunoisolation (Culture flo; Asahi Medical Co. Ltd., of the modules was replaced once with warm saline and
Tokyo, Japan) was used for culture of these cells [3]. In then arterial blood of the dog was flowed in the system.
short, the fiber was made by polyethylene, with surface During the experiment, the capillary lumen was perfused
area being 200 cm2. About 1  108 cells were injected with blood (10 mL/min) while the pericapillary side was
to each module with acid soluble type I collagen (Sigma, counter-currently perfused with an artificial solution for
St. Louis, MO, USA) at 8 days before the experiment. hemofiltration (Sublood; Fuso Pharmaceutical Co.
Once 1/8 of total cells were injected, culture medium Ltd., Osaka, Japan; composition in mmol/L, 140 Na,
was started to circulate at 0.1 mL/min for 30 minutes 2K, 3.5 Ca, 1 Mg, 110 Cl, 3.5 acetate, 25
following a 15-minute equilibration period. Next, the HCO3 , 0.52 glucose, 10 mL/min). Inulin was continu-
module was rotated 45 around the long axis and the ously infused (20 mg/dL) from the arterial side of the
same procedure was repeated. These procedures were module. Nafamostat mesilate (15 mg/h; Futhan; Torii
performed to seed the cells equally in the module. After Pharmaceutical Co. Ltd., Tokyo, Japan) was continu-
the cell injection for eight times, capillary side of the ously infused from the arterial side for anticoagulation
during the procedure.module was perfused with culture medium [Dulbecco’s
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During the treatment, arterial blood was drawn just
before and at 30, 60 and 90 minutes after the initiation
of the study to measure serum concentrations of digoxin,
inulin and granulocyte elastase, and complete the blood
cell count. Venous blood (just at the post-hybrid kidney)
was also obtained at 30, 60 and 90 minutes after the
initiation to measure same parameters. The digoxin and
inulin concentrations of the artificial solution in the peri-
capillary side were determined also. Serum digoxin and
inulin concentrations were measured by a monoclonal
polarization immunoassay technique (TDx autoana-
lyzer; Dinabot Co.) [6] and the modified Jaffe’s method
with an autoanalyzer [7]. Granulocyte elastase was mea-
sured by an enzyme immunoassay (PMN elastase kit;
Merck Immunoassay, Darmstadt, Germany) [8].
The effects of hemodialysis with a machine not using
cultured cells also were evaluated in digoxin-intoxicated
dogs under a similar protocol.
Statistics
All data are shown as the mean SE. Statistical evalu-
ation was performed by one-way ANOVA and t test as
appropriate. A P value less than 0.05 was regarded as
Fig. 2. Change of serum digoxin concentration during the treatmentsignificant. with renal proximal tubule cell line-multidrug resistant protein (PCTL-
MDR) (A), PCTL (B) and control (without cell; C ). Symbols are: ()
arterial; () venous; #P  0.05 vs. 0 min; †P  0.05 vs. arterial.
RESULTS
After three days of the digoxin injection, all animals
suffered from anorexia and lost body weight. Mean se-
that flowed out from the pericapillary side of the modulesrum digoxin concentration just before the treatment was
is shown in Figure 3A. It was significantly higher by2.89 0.10 ng/mL (N 14). Effects on the serum digoxin
PCTL-MDR than by PCTL (3.4  0.5 and 0.3  0.1concentration of the hybrid kidney with PCTL-MDR
mg/90 min for PCTL-MDR and PCTL, respectively). Inwas shown in Figure 2A. The concentration of arterial
the absence of cell culture, it was slightly higher (1.0 side was dramatically reduced at 30 minutes after the
0.3 mg/90 min) than PCTL alone, but less than the PCTL-initiation and continued to decrease until the end of
MDR group. The calculated digoxin clearance (that is,the treatment. Digoxin concentration at 90 minutes after
amount of drug removed/mean arterial concentration)the initiation of the treatment was 0.92  0.11 ng/mL
is shown in Figure 3B. It was about 15-fold greater in(N  7). The concentrations of venous side were signifi-
PCTL-MDR than in PCTL alone, and still about fourfoldcantly lower than those of arterial side at each observation
higher than the cell culture-free system.point. Although treatment with PCTL alone also slightly
Changes of serum inulin concentration at arterial andbut significantly reduced serum digoxin concentration,
venous sides were monitored to verify the absence ofthe decrement was significantly smaller than that with
leakage of the modules. This parameter was not changedPCTL-MDR (Fig. 2B). In order to compare the efficacy
during the treatment with PCTL-MDR or PCTL (Fig. 4).of this equipment with that of an ordinary artificial kid-
The serum inulin concentration in the artificial solutionney, complementary studies were conducted in which
drained from pericapillary side was lower than the detec-hemodialysis was performed in the absence of cultured
tion threshold (0.5 mg/dL) in the PCTL-MDR and PCTLcells (Fig. 2C). As can be seen, the slope of the decrease
groups. Clearance of digoxin and inulin in the PCTLin the arterial digitalis concentration was steeper than
alone group was lower than those in the control group.that of the hybrid kidney with PCTL alone, but less steep
These results are compatible with our previous in vitrothan that of the hybrid kidney with PCTL-MDR. The
data [3], and we believe that it may be because theseapparent elimination half-life of digoxin in the experi-
solutes can pass more easily through the dialyzer mem-ment with each type of module was 47.5  3.4, 212.1 
brane alone than through the membrane with PCTL.10.3 and 173.2  7.7 minutes in the PCTL-MDR, PCTL
Several parameters were measured to evaluate possi-and control groups, respectively. Digoxin removal esti-
mated by the amount of the drug in the artificial solution ble adverse reactions by this procedure. The change of
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Fig. 5. Changes of complete blood count during the treatment. (A)
Hematocrit. (B) White blood cell count. (C ) Platelet count. SymbolsFig. 3. Calculated amount of digoxin removal (A) and its clearance
are: () PCTL-MDR; () PCTL; #P  0.05 vs. 0 min.(B). *P  0.05 vs. PCTL; †P  0.05 vs. control.
Fig. 6. Change of serum granulocyte elastase during the treatment.
Changes in the white blood cell count and platelets at
the arterial side are shown in Figure 5 panels B and C,
respectively. They were slightly but significantly reduced
by the treatment, however, there was no difference be-
tween the PCTL-MDR and PCTL modules.
Serum granulocyte elastase from arterial blood was
measured to evaluate the biocompatibility of the module.
Figure 6 shows that, although the variable was signifi-
Fig. 4. Change of serum inulin concentration during the treatment with cantly increased after the treatment, the change was notPCTL-MDR (A), PCTL (B) and control (without cell; C ). Symbols
significantly different between the PCTL-MDR andare: () arterial; () venous; #P  0.05 vs. arterial.
PCTL modules.
hematocrit is shown in Figure 5A. Although a little clot-
DISCUSSIONting was observed in the module during the treatment,
the hematocrit value did not significantly decrease after This study extends our previous in vitro finding of a
selective removal of digoxin, a substrate of MDR-1, bythe treatment in either the PCTL-MDR or PCTL group.
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a tissue engineering system applied for the treatment of have to start the cell culture before the intoxication is
detected, which is a disadvantage of this system. For futuredigoxin-intoxicated dogs. As expected, the application
of this device in vivo removed a larger amount of digoxin, clinical situations, we believe that the cells could be con-
tinuously cultured in the device and thus be available inwhich was sufficient to reduce its serum concentration.
To our knowledge, this is the first report showing the case of intoxication. If we can establish such a system,
this device may be useful even in the clinical situation.usefulness of the hybrid kidney with the introduction of
a responsible gene to renal cells for the treatment of We also measured serum granulocyte elastase to eval-
uate the biocompatibility of this system [11], and withdrug intoxication.
Hemoperfusion with activated charcoal is frequently the treatment found it increased. As the increment was
much lower than that by cardiopulmonary bypass in dogsused to treat digoxin intoxication, but it has some disad-
vantages [1, 2]. First, removal of the substance is not [8], we think that such a change is acceptable. Nafamostat
mesilate, which we used as the anticoagulant, is reportedspecific, and physiologically important materials in the
body, such as protein and platelets, also are removed. to protect neutrophil activation during hemodialysis and
cardiopulmonary bypass [12, 13] and hybrid liver [14].Thrombocytopenia is frequently observed in clinical situ-
ations after the procedure. We have previously reported This agent might lead to the better biocompatibility of
our system.that thrombocytopenia was seen in dogs with digoxin
intoxication that had been hemoperfused with charcoal We have recently reported that a 	2-microglobulin
adsorption column for the treatment of amyloidosis asso-[4]. Although the blood flow rates were not identical and
therefore impossible to compare precisely, the platelet ciated with renal failure also possesses a higher capacity
for digoxin clearance [4]. Although the apparent clear-count was reduced from 205,600  7842 to 32,340 
6570/L (83.5% reduction) using the three-hour treat- ance seems to be greater than observed in the present
study, precise comparison is impossible because of differ-ment with charcoal. These data suggest that the severity
of thrombocytopenia was mild and also that the removal ent blood flow rates between the two devices. To achieve
a higher efficacy, the device must be improved to endureof digoxin is more specific during the treatment with
the hybrid kidney. Our finding that inulin transport was the higher blood flow rate. On the other hand, the ad-
sorption column has some disadvantages such as thenegligible by this system also supports this hypothesis.
The second disadvantage of the charcoal is its low trans- larger reduction of red blood cells, platelets and albumin
than those observed in the present device.port capacity. Our previous study showed that the esti-
mated capacity to remove digoxin by charcoal is about Hybrid organs with tissue engineering have been re-
ported mainly in primary cultures of hepatocytes for the8.69 mg/3 h at a 50 mL/min of blood flow rate [4], which
is only about 26% of capacity of the hybrid kidney ob- treatment of liver failure [15, 16]. Recently, a hybrid organ
with renal cells was reported for the treatment of acutetained in our current study. Although the blood flow rate
was not same with this study and thus a precise compari- renal failure in dogs [17]. Although that report used
primary culture of renal cells, it would be better to intro-son is impossible, we speculate that our novel system has
a higher capacity, and may be superior to conventional duce specific gene(s) to the cells if the modified cells
have the enhanced transport capacity of the substrates.hemoperfusion with respect to both efficacy and safety.
Indeed, with this device digoxin clearance is almost equiv- If we obtain gene-introduced cells that possess specific
physiological/pharmacological functions, such cells mayalent to its renal clearance and about half of total body
clearance in normal dogs [9]. For the treatment of human apply to this new cell culture system and thus provide
specific functions to patients. Thus, our system may besubjects, this system should be up-scaled more than five-
fold because digoxin clearance in humans is about 100 mL/ useful not only for the treatment of digoxin intoxication,
but also for compensation of physiological function. Ifmin [10]. Further evaluation is needed before applying
this system to human subjects. The priming volume of the elimination mechanisms of uremic toxin(s) from the
kidney are fully understood, a hybrid kidney with anthe whole system in our current study is about 110 mL;
the volume for each mini-module is about 5 mL and the introduction of the genes to renal cells may be a more
powerful tool for the treatment of renal failure. Wevolume of tubing to connect the whole system is about
60 mL. Because this system requires that it be scaled up seeded the cells on the outside of the hollow fiber, while
Humes et al seeded on the inside [17]. We believe thatto about fivefold for humans and it is complicated, it
needs to be modified and simplified for clinical situations. there are two advantages in our system. (1) We are afraid
that because the inner diameter of the module is veryTreatment of digoxin intoxication should be required
for emergency situations. As described in our earlier small, cells cultured on the inner surfaces of the fibers
may obstruct blood flow during the treatment. (2) Therearticle, we need to wait about a week to use this column
after the culture is started [3]. In addition, the maximum is a concern about the contact of non-human cells with
human blood during the treatment. Because of speciescapacity of drug removal in this device can be obtained
on days 7 to 10 after the cells are cultured [3]. Thus, we difference, unexpected immunological problems might
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4. Tsuruoka S, Osono E, Nishiki K, et al: Removal of digoxin byoccur in clinical situations. By seeding cells to outside
column for specific adsorption of beta(2)-microglobulin: A poten-
of the fiber, such problems might be avoided. tial use for digoxin intoxication. Clin Pharmacol Ther 69:422–
430, 2001In summary, we evaluated the efficacy of a novel arti-
5. Ueda K, Cardarelli C, Gottesman MM, et al: Expression of aficial hybrid kidney with the introduction of MDR-1, by
full-length cDNA for the human “MDR1” gene confers resistance
parallel connection of 10 hollow-fiber systems in dogs to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci USA
84:3004–3008, 1987with digoxin intoxication. As expected from our previous
6. Ferreri LF, Raisys VA, Opheim KE: Analysis of digoxin concen-in vitro study, this system can selectively remove the
trations in serum by fluorescence polarization immunoassay: An
drug from circulating blood to the extent that is sufficient evaluation. J Anal Toxicol 8:138–140, 1984
7. Fjeldbo W, Stamey TA: Adapted method for determination ofto reduce its serum concentration to a therapeutic range
inulin in serum and urine with an AutoAnalyzer. J Lab Clin Medby 90 minutes of the treatment. Compared to activated
72:353–358, 1968
charcoal, the capacity of drug removal with this system 8. Yamazaki T, Ooshima H, Usui A, et al: Protective effects of ONO-
5046*Na, a specific neutrophil elastase inhibitor, on postperfusionwas higher. The biocompatibility of this device in dogs
lung injury. Ann Thorac Surg 68:2141–2146, 1999was relatively acceptable. While our results are encour-
9. Gierke KD, Perrier D, Mayersohn M, et al: Digoxin disposition
aging, further studies are needed to apply this device to kinetics in dogs before and during azotemia. J Pharmacol Exp
Ther 205:459–464, 1978renal patients.
10. MacFarland R, Moeller V, Pieniaszek H, et al: Assessment of
the potential pharmacokinetic interaction between digoxin and
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